{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:24:59Z","timestamp":1775251499244,"version":"3.50.1"},"reference-count":5,"publisher":"American Diabetes Association","issue":"11","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA1c from baseline after 24 weeks (\u0394HbA1c).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Mean \u00b1 SD baseline HbA1c was 7.1 \u00b1 0.7% (54 \u00b1 5 mmol\/mol; n = 37) and 7.4 \u00b1 0.6% (57 \u00b1 5 mmol\/mol; n = 39) in the methazolamide and placebo groups, respectively. Methazolamide treatment was associated with a \u0394HbA1c of \u20130.39% (95% CI \u20130.82, 0.04; P &amp;lt; 0.05) (\u20134.3 mmol\/mol [\u20139.0, 0.4]), an increase in the proportion of patients achieving HbA1c \u22646.5% (48 mmol\/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (\u223c10 units\/L), and weight loss (2%) in metformin-cotreated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc14-1038","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T09:05:13Z","timestamp":1408093513000},"page":"3121-3123","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study"],"prefix":"10.2337","volume":"37","author":[{"given":"Richard W.","family":"Simpson","sequence":"first","affiliation":[{"name":"Box Hill Hospital, Box Hill, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey C.","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biomedical Sciences, Geelong Hospital, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Proietto","sequence":"additional","affiliation":[{"name":"Heidelberg Repatriation Hospital, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Sarah","sequence":"additional","affiliation":[{"name":"Clinical Trial Unit, Department of Medicine, Barwon Health, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerrie M.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biomedical Sciences, Geelong Hospital, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Phillips","sequence":"additional","affiliation":[{"name":"Box Hill Hospital, Box Hill, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Chambers","sequence":"additional","affiliation":[{"name":"Clinical Trial Unit, Department of Medicine, Barwon Health, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"MacGinley","sequence":"additional","affiliation":[{"name":"Deakin University, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Orford","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Barwon Health\/Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Walder","sequence":"additional","affiliation":[{"name":"Deakin University, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Krippner","sequence":"additional","affiliation":[{"name":"Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Skoff","sequence":"additional","affiliation":[{"name":"Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent J.","family":"Wacher","sequence":"additional","affiliation":[{"name":"Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2014,10,10]]},"reference":[{"key":"2022031219304887900_B1","year":"2013"},{"key":"2022031219304887900_B2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1152\/physiolgenomics.00115.2010","article-title":"A gene expression signature for insulin resistance","volume":"43","author":"Konstantopoulos","year":"2011","journal-title":"Physiol Genomics"},{"key":"2022031219304887900_B3","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.2337\/db11-0578","article-title":"Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo","volume":"61","author":"Konstantopoulos","year":"2012","journal-title":"Diabetes"},{"key":"2022031219304887900_B4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/nyas.12016","article-title":"Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals","volume":"1281","author":"Masuoka","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"2022031219304887900_B5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/dmrr.666","article-title":"Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease","volume":"22","author":"Schindhelm","year":"2006","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/11\/3121\/620640\/3121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/11\/3121\/620640\/3121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T16:06:52Z","timestamp":1647101212000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/11\/3121\/29270\/Efficacy-and-Safety-of-Oral-Methazolamide-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,10]]},"references-count":5,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,10,10]]},"published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-1038","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718533941.793499041","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,10]]}}}